Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881062 · ClinicalTrials.gov registry record · Phase 1
Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females
A Phase 1 study of Metabolism and Absorption, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00881062: Completed Phase 1 study of Metabolism and Absorption, sponsored by Repros Therapeutics.
NCT00881062 is a Phase 1 study of Metabolism and Absorption that has completed, run by Repros Therapeutics. The registered enrollment target is 6 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00881062, a Phase 1 study of Metabolism and Absorption, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was to determine the ADME and metabolites of Proellex following a single oral dose of 25 mg.
Conditions Studied
Interventions
- DRUG Proellex
Study Locations (1)
Wisconsin
- Covance Clinical Research Unit Inc. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00881062 record still lists
NCT00881062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Proellex is the first listed.
NCT00881062 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00881062 about?
NCT00881062 is a clinical study titled "Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females". This study was to determine the ADME and metabolites of Proellex following a single oral dose of 25 mg.
What is the current status of trial NCT00881062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-04. Estimated completion is 2009-06.
What conditions does trial NCT00881062 study?
This clinical trial studies the following conditions: Metabolism, Absorption, Excretion.
What interventions are being tested in trial NCT00881062?
The interventions under investigation include: Proellex (DRUG).
Who is sponsoring clinical trial NCT00881062?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00881062 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00881062's enrollment target sits among peer trials
6 19th of 19 the lowest of 19 other Metabolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
COMPLETED · Phase 1
-
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
COMPLETED · Phase 1
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
RECRUITING
-
Caloric Balance Markers Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia